Treatment of Multifocal Cutaneous Langerhans Cell Histiocytosis in Adults
When Langerhans cell histiocytosis presents in an adult with skin-only disease involving multiple cutaneous sites, the management approach is shaped specifically by the multifocal extent of involvement and the adult patient context.
Clinical Scenario
Multifocal cutaneous LCH confined to the skin, with lesions spanning more than a single area, in an adult patient. Disease is limited to the skin but is not isolated to one localised site.
Treatment Approach
Management of multifocal cutaneous LCH in adults involves topical agents for limited skin areas, with systemic oral therapy considered when cutaneous involvement is more widespread. The complete protocol — including the full range of options and the approach to refractory disease — is available in the structured regimen below.
References
DOI: 10.1182/blood.2021014343
For multifocal cutaneous LCH, recommended treatments are topical therapy, oral low-dose weekly methotrexate ± prednisone/6-MP, hydroxyurea, or IMiDs.
Topical triamcinolone can be used for disease involving small areas of the skin.
Multifocal skin disease is usually responsive to hydroxyurea, IMiDs, oral low-dose methotrexate therapy with or without prednisone/6-mercaptopurine.
In refractory cases, local therapy with imiquimod, 20% N-mustard, or irradiation can be effective.
View source ↗